Treating Canine Cancer with Killer T Cells

Watch On Demand

Originally recorded on December 9, 2021

Recent advances in the fourth pillar of cancer treatment—immunotherapy—suggest that the immune system may be our best tool to cure more cancers. Join us to learn more about how the move to an immunotherapeutic approach to treat canine cancer can make a difference for your patients and their families.

Dr. Wayne Carter, CEO of TVAX Biomedical describes the science supporting adoptive cell therapy and the critical role that T cells play in patrolling the body to identify and kill bacterial, viral, and other threats, including cancer. Dr. Noe Reyes, CMO of ELIAS Animal Health, reviews the ELIAS Cancer Immunotherapy protocol and results from a clinical study of the treatment for canine osteosarcoma. Dr. Julie Bulman-Fleming discusses what makes this treatment approach attractive to pet owners, the side effects she observed in her patients, and the key items to consider when implementing this new immunotherapy approach into an oncology practice. Finally, Dr. Brooke reviews her experiences implementing this approach in her oncology practice, the ease of following the treatment protocol, and the side effects she observed in her patients.

Key learning objectives:

  • Learn how this pioneering approach to canine cancer treatment harnesses the power of the immune system
  • Understand how this immunotherapeutic approach can differentiate your practice, whether you are a specialty hospital or a general practice clinic
  • Find out how you can offer an innovative treatment option to pet owners looking for a new way to care for a valued member of their family


Wayne Carter, DVM, DACVIM, PhD

President & CEO, TVAX Biomedical

Dr. Wayne Carter joined TVAX Biomedical in 2019 and serves as a member of the Board of Directors. Prior to that, he served as the President and CEO of BioNexus KC leading the transformation of the Kansas City region into a nationally recognized center of excellence in human and animal health research, development and commercialization. Dr. Carter has more than 18 years of Fortune 500 experience in pharmaceutical and nutrition R&D, and in his role at Pfizer as Executive Director of Global Clinical Development, he accelerated the development of many drugs using novel clinical technologies. His board appointments include ImpeDx, MRI Global, University of Kansas Center for Research, University of Missouri Research and Development, and the One Health Commission. Dr. Carter received his BS, DVM, and PhD in Immunology from Purdue University

Julie Bulman-Fleming, DVM, DACVIM (Oncology)

Veterinary Oncologist, Veterinary Cancer Group

Dr. Bulman-Fleming attended the University of British Columbia for her bachelor’s degree in animal biology and obtained her veterinary medical degree at the Western College of Veterinary Medicine in Saskatoon, Saskatchewan, where she developed an interest in oncology. After graduating, she completed a rotating internship in small animal medicine, surgery and critical/emergency care. Dr. Bulman-Fleming joined Veterinary Cancer Group in Tustin, CA as a medical oncology resident in August 2008, completing the three-year program in 2011. She has a particular interest in client education, palliative care and the role of the immune system in cancer development and treatment. Dr. Bulman-Fleming participated in the recent ELIAS Animal Health canine osteosarcoma clinical trial and looks forward to sharing her experience and insights from the study.

Brooke Fowler, DVM, MS, DACVIM (Oncology)

Veterinary Oncologist, Colorado Animal Specialty & Emergency

Dr. Fowler is a veterinary oncologist at Colorado Animal Specialty & Emergency (formerly Aspen Meadow Veterinary Specialists) in Boulder, Colorado. She completed her undergraduate education at the University of Michigan in Ann Arbor and earned her Doctor of Veterinary Medicine degree at the University of Illinois in Champaign, Illinois. Dr. Fowler then completed a rotating internship at a private practice in Chicago, as well as an oncology internship and three-year residency at the University of Missouri. During her residency, she obtained a master’s degree with a special focus on the immune system as it relates to cancer. Dr. Fowler participated in the recent ELIAS Animal Health canine osteosarcoma clinical trial and is excited to share her experience and insights from the study.

Noe Reyes, DVM

Chief Medical Officer, ELIAS Animal Health

As Chief Medical Officer for ELIAS Animal Health, Dr. Reyes brings more than 20 years of experience as both a veterinarian and animal health researcher. He has served as Chief Medical Officer of ELIAS since 2016 and has been a member of the company’s Scientific Advisory Board since its founding in 2015. Dr. Reyes is a graduate of the University of California, Davis (BS, DVM).